Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

Revista Brasileira de Hematologia e Hemoterapia

Volumn 36, Issue 1, 2014, Pages 54-59

  de Almeida, Maria Helena ^a   Fogliatto, Laura ^b   Couto, Dulce ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

BCR ABL positive; Leukemia, chronic myeloid; Patient compliance; Therapeutics

Indexed keywords

BCR ABL TYROSINE KINASE INHIBITOR; DASATINIB; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CELL COUNT; BODY DISTRIBUTION; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; COMPUTER PROGRAM; COUNSELING; DEPRESSION; DIARRHEA; DOCTOR PATIENT RELATION; DRUG ABSORPTION; ECHOCARDIOGRAPHY; ECONOMIC ASPECT; EDUCATION; EVENT FREE SURVIVAL; GASTROINTESTINAL DISEASE; HEALTH CARE PERSONNEL; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER TOXICITY; MACULOPAPULAR RASH; MEDICAL RECORD; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MICROELECTRONIC MONITORING SYSTEM; MUSCLE SPASM; MYALGIA; PANCREAS DISEASE; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL EDEMA; PLEURA EFFUSION; REVIEW; SELF REPORT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84897821802     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20140014     Document Type: Review

References (27)

1. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10(1):14-24.
2. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009:477-87.
3. Quintas-Cardama A, Cortes JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008; (Suppl 3):S82-8.
4. Bordonaro S, Raiti F, Di Mari A, Lopiano C, Romano F, Pumo V, et al. Active home-based cancer treatment. J Multidiscip Healthc. 2012;5:137-43.
5. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8.
6. World Health Organization. Adherence to long-term therapies: evidence for action [Internet]. 2003 [cited 2012 Nov 29]. Available from: http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf
7. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-11.
8. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652-61. Comment in: J Natl Cancer Inst. 2002; 94(21):1652; author reply 1652.
9. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
10. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004;13(1):11-9.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. Comment in: N Engl J Med. 2005;353(18):1972-4; author reply 1972-4.
12. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46(2):163-8. Comment in: Clin Pharmacol Ther. 1990; 47(4):547.
13. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther. 1989;46(2):169-76.
14. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733-6.
15. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471-4.
16. Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012;28(2):213-9. Comment in: Curr Med Res Opin. 2012;28(7):1164; author reply 1164-5.
17. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and nonadherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6):481-96.
18. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, et al. Healthcare resource utilization and costs associated with nonadherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61-9.
19. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626-30.
20. Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010;363(6):596-8.
21. Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904-9. Comment in: Br J Cancer. 2012;107(6):901-3
22. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011;25(2):201-10.
23. Jonsson S, Olsson B, Soderberg J, Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann Hematol. 2012;91(5):679-85.
24. Moon JH, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol. 2012;29(2):1179-85.
25. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)-Chronic Myelogenous Leukemia. Version 2.2013 [Internet]. 2013 [cited 2012 Nov 29] Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
26. Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev. 2012;38(3):241-8.
27. Galinsky I, Buchanan S. Practical management of dasatinib for maximum patient benefit. Clin J Oncol Nurs. 2009;13(3):329-35.